RAD001 in Advanced Sarcoma
This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.
Soft Tissue Sarcomas|Bone Sarcomas
DRUG: RAD001
Progression-free survival rate at 16 weeks, Determined as the proportion of progression-free (complete response, partial response and stable disease) at 16 weeks of treatment, 16 weeks
Progression-free survival, Defined as the time from the initiation of everolimus to disease progression or death, whichever occurred first., Up to 24 months|Overall survival, Defined from the initiation of everolimus to death of any cause., Up to 24 months|Response rate, Defined as the proportion of complete response and partial response per RECIST criteria., Up to 24 months|Toxicity, Any adverse events occurred during the treatment with study drug., Up to 24 months
This multicenter, phase II trial evaluated the efficacy and safety of everolimus in patients with metastatic or recurrent bone and soft tissue sarcoma after failure of anthracycline and/or ifosfamide.